Brief: Chinook Therapeutics Says BION-1301 Remains Well-Tolerated in Phase 1/2

Chinook Therapeutics

19/05/2022 07:12

May 19 (Reuters) - Chinook Therapeutics Inc  KDNY.O :
    * CHINOOK THERAPEUTICS- BION-1301 REMAINS WELL-TOLERATED,
WITH NO
SERIOUS ADVERSE EVENTS AND NO TREATMENT DISCONTINUATIONS DUE TO
ADVERSE EVENTS
    * CHINOOK THERAPEUTICS INC - ALL PATIENTS WITH IGAN IN
COHORT 1
HAVE TRANSITIONED TO SUBCUTANEOUS (SC) DOSING
    * CHINOOK THERAPEUTICS -DATA FROM TRIAL WILL INFORM DESIGN
OF
PHASE 3 TRIAL OF BION-1301 FOR PATIENTS WITH IGAN THAT CO PLANS
TO INITIATE IN 2023
    * CHINOOK THERAPEUTICS - BION-1301 DEMONSTRATED 50%
PROTEINURIA
REDUCTION IN PATIENTS WITH IGAN AFTER THREE TO SIX MONTHS OF
TREATMENT

Source text for Eikon:  ID:nGNX3zlm1t 
Further company coverage:  KDNY.O 

 ((Reuters.Brief@thomsonreuters.com;))